Td Asset Management Inc Exelixis, Inc. Transaction History

Td Asset Management Inc

$107 Billion
Q3 2024

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	SELL	$20.17 - $23.93 $858,677 - $1.02 Million	-42,572 Reduced 23.54%	138,272 $3.28 Million
Q4 2023 Feb 12, 2024	SELL	$19.25 - $24.13 $2.46 Million - $3.09 Million	-127,968 Reduced 41.44%	180,844 $4.34 Million
Q3 2023 Oct 27, 2023	BUY	$19.04 - $22.74 $2.36 Million - $2.81 Million	123,706 Added 66.83%	308,812 $6.75 Million
Q2 2023 Aug 09, 2023	BUY	$18.17 - $20.48 $218,221 - $245,964	12,010 Added 6.94%	185,106 $3.54 Million
Q1 2023 May 10, 2023	SELL	$16.3 - $19.41 $159,740 - $190,218	-9,800 Reduced 5.36%	173,096 $3.36 Million
Q4 2022 Feb 06, 2023	SELL	$14.96 - $17.39 $5.94 Million - $6.9 Million	-397,039 Reduced 68.46%	182,896 $2.93 Million
Q3 2022 Nov 07, 2022	SELL	$15.68 - $22.27 $710,304 - $1.01 Million	-45,300 Reduced 7.25%	579,935 $9.19 Million
Q2 2022 Aug 04, 2022	SELL	$17.44 - $23.16 $1.65 Million - $2.2 Million	-94,800 Reduced 13.17%	625,235 $13 Million
Q1 2022 May 10, 2022	SELL	$17.03 - $22.67 $1.74 Million - $2.32 Million	-102,400 Reduced 12.45%	720,035 $16.3 Million
Q4 2021 Feb 10, 2022	BUY	$15.84 - $21.88 $3.78 Million - $5.22 Million	238,437 Added 40.83%	822,435 $15 Million
Q3 2021 Nov 09, 2021	SELL	$16.3 - $21.14 $317,850 - $412,230	-19,500 Reduced 3.23%	583,998 $12.3 Million
Q2 2021 Aug 11, 2021	SELL	$17.95 - $25.56 $480,701 - $684,496	-26,780 Reduced 4.25%	603,498 $10.2 Million
Q1 2021 May 14, 2021	BUY	$20.53 - $25.22 $3.35 Million - $4.11 Million	163,155 Added 34.93%	630,278 $14.2 Million
Q4 2020 Feb 16, 2021	BUY	$18.39 - $24.8 $2.82 Million - $3.8 Million	153,346 Added 48.87%	467,123 $9.38 Million
Q3 2020 Nov 10, 2020	SELL	$20.67 - $26.94 $99,216 - $129,312	-4,800 Reduced 1.51%	313,777 $7.67 Million
Q2 2020 Aug 13, 2020	BUY	$16.46 - $27.42 $1.38 Million - $2.31 Million	84,123 Added 35.88%	318,577 $7.56 Million
Q1 2020 May 15, 2020	BUY	$14.46 - $21.8 $1.6 Million - $2.41 Million	110,506 Added 89.16%	234,454 $4.04 Million
Q4 2019 Feb 11, 2020	SELL	$15.15 - $18.89 $462,075 - $576,145	-30,500 Reduced 19.75%	123,948 $2.18 Million
Q3 2019 Nov 07, 2019	BUY	$17.68 - $22.65 $129,064 - $165,345	7,300 Added 4.96%	154,448 $2.73 Million
Q2 2019 Aug 01, 2019	BUY	$18.93 - $24.75 $535,719 - $700,425	28,300 Added 23.81%	147,148 $3.15 Million
Q1 2019 May 08, 2019	BUY	$19.6 - $24.76 $1.13 Million - $1.43 Million	57,900 Added 95.0%	118,848 $2.83 Million
Q4 2018 Feb 01, 2019	SELL	$13.65 - $21.8 $99,645 - $159,140	-7,300 Reduced 10.7%	60,948 $1.2 Million
Q3 2018 Nov 01, 2018	SELL	$15.87 - $22.4 $426,903 - $602,560	-26,900 Reduced 28.27%	68,248 $1.21 Million
Q2 2018 Jul 31, 2018	SELL	$18.56 - $22.45 $1.89 Million - $2.29 Million	-101,932 Reduced 51.72%	95,148 $2.05 Million
Q1 2018 May 11, 2018	BUY	$22.15 - $31.89 $522,739 - $752,604	23,600 Added 13.6%	197,080 $4.37 Million
Q4 2017 Feb 02, 2018	SELL	$24.23 - $30.93 $31,499 - $40,209	-1,300 Reduced 0.74%	173,480 $5.27 Million
Q3 2017 Nov 09, 2017	BUY	$23.35 - $29.24 $4.08 Million - $5.11 Million	174,780	174,780 $4.24 Million

Others Institutions Holding EXEL

# of Institutions

503

Shares Held

244M

Call Options Held

2.54M

Put Options Held

2.29M

Black Rock Inc. New York, NY

33.5M
Shares

$1.2 Billion
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

29.3M
Shares

$1.05 Billion
0.01% of portfolio
Farallon Capital Management LLC San Francisco, CA

25.4M
Shares

$913 Million
3.31% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

15.4M
Shares

$552 Million
0.63% of portfolio
State Street Corp Boston, MA

11.4M
Shares

$411 Million
0.01% of portfolio

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.6B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Td Asset Management Inc with notifications on news.

Account